Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Imidazole SCHEMBL1936380 | 1.00 | — | — | |
| Imidazole SCHEMBL113116 | 1.00 | — | — | |
| Imidazole SCHEMBL2369283 | 1.00 | ALDH1A1 (0.93) | ALDH1A1FKBP5 | |
| Imidazole SCHEMBL15813745 | 0.97 | — | — | |
| Imidazole SCHEMBL28046402 | 0.97 | — | — | |
| Imidazole SCHEMBL28046413 | 0.97 | — | — | |
| Imidazole SCHEMBL1445454 | 0.97 | — | — | |
| Imidazole SCHEMBL11803881 | 0.97 | — | — | |
| Imidazole SCHEMBL28478036 | 0.97 | — | — | |
| Imidazole SCHEMBL2684565 | 0.96 | ALDH1A1 (1.00) | ALDH1A1FKBP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3130343-B1 | POLYIMIDAZOLES FOR USE AS BILE ACID SEQUESTRANTS | RELYPSA INC (US) | 2018-05-09 | — | — | EP | disclosed |
| EP-3130343-A1 | POLYIMIDAZOLES FOR USE AS BILE ACID SEQUESTRANTS | Relypsa, Inc. (US) | 2017-02-15 | — | — | EP | disclosed |
| US-20130189215-A1 | POLYIMIDAZOLES FOR USE AS BILE ACID SEQUESTRANTS | RELYPSA, INC. (US) | 2013-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130189215-A1 | POLYIMIDAZOLES FOR USE AS BILE ACID SEQUESTRANTS | NR1H4, SLC10A2, ITCH | ALDH1A1 4043/4885FKBP5 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.